|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Laboratory of Clinical Investigation,
Laboratory of Immunoregulation, and Laboratory of Immunology, National
Institute of Allergy and Infectious Diseases; Genetic Epidemiology
Branch, and Laboratory of Pathology, National Cancer Institute;
Immunology Service, Clinical Pathology Department, Clinical Center, and
Genetics and Molecular Biology Branch, National Human Genome Research
Institute, National Institutes of Health, Bethesda, MD; Department of
Medicine, Weill Medical College of Cornell University, New York,
NY; Kinderklinik der TU Dresden and Labor Klinische Forschung,
Dresden, Germany; University Children's Hospital, Freiburg, Germany;
and Pathologisches Institute der Universität, Wurzburg, Germany.
Lymphomas were studied in kindreds with autoimmune
lymphoproliferative syndrome (ALPS; Canale-Smith syndrome), a disorder of lymphocyte homeostasis usually associated with germline Fas mutations. Fas (CD95/APO-1) is a cell surface receptor that initiates programmed cell death, or apoptosis, of activated lymphocytes. Lymphoma
phenotype was determined by immunohistochemistry, frequency of
CD3+CD4 Chromosomal translocations leading to the
dysregulation of cell division and differentiation contribute to
lymphomagenesis.1-3 Another genetic mechanism that
contributes to lymphoma development is the acquired failure of
lymphocytes to be susceptible to programmed cell death, or apoptosis.
Some lymphoma cells overexpress Bcl-2, a protein that inhibits
apoptosis.4-6 Each of these predisposing molecular and
cytogenetic defects arise within individual somatic cells, but it is
unclear whether they relate to the hereditary risk for lymphoma.
The recent recognition of the autoimmune lymphoproliferative
syndrome (ALPS; also called the Canale-Smith syndrome) afforded us the
opportunity to explore its cause, inherited defects in genes that
promote lymphocyte apoptosis, as an additional contributor to lymphoma
development.7-18 ALPS is characterized by chronic lymphadenopathy and splenomegaly of early onset, autoimmune phenomena, and expanded populations of T-cell receptor Fas is a transmembrane receptor in the tumor necrosis factor receptor
(TNFR) gene family. B- and T- lymphocyte apoptosis is initiated by binding of the Fas ligand to Fas.19 Fas
transduces the death signal through its cytoplasmic "death domain,"
the binding site for proteins that activate cysteine proteases
(caspases) that mediate the apoptosis cascade.20-22 The
prominent lymphoid abnormalities in ALPS in the absence of significant
pathology in other organ systems suggest that the Fas-Fas ligand
apoptosis pathway has 2 primary roles: the elimination of unneeded and
potentially deleterious lymphocytes, and the killing of virus-infected
cells.19 We now ask whether Fas-mediated apoptosis plays a
role in the prevention of lymphoid malignancy.
Study subjects
All individuals with ALPS-like features within these families with Fas
mutations and their available relatives in each of the study centers
were enrolled after written informed consent in institutional review
board-approved research protocols. All amenable subjects were examined
and bled for extensive studies. In all, 223 persons in 39 families were evaluated.
Case definition
Flow cytometry analysis The lymphocyte phenotypes of peripheral blood mononuclear cells (PBMCs) were determined at each study site by 2- or 3-color flow cytometry, as reported.8,10,11,15,23Immunohistochemical analysis Hematoxylin and eosin-stained sections from formalin- or B5-fixed paraffin-embedded tissue blocks were prepared, and immunophenotypic studies were performed on unstained paraffin sections with a panel of antibodies, as described previously.24,25Detection of Fas gene mutation Genomic DNA was prepared from PBMCs or paraffin-embedded tissue blocks from deceased individuals and screened for Fas mutations using described methods.8,10,23,26Cell culture and stimulation The PBMCs were separated from heparinized venous blood or buffy coat fractions by Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) density gradients. PBMCs at 106/mL were activated with 10 µg/mL phytohemagglutinin (PHA) in RPMI 1640 with 10% fetal calf serum, 2 mM glutamine, and penicillin-streptomycin. Cultures were maintained in recombinant human interleukin 2 (IL-2) (100-200 IU/mL) (Midwest Medical, Bridgeton, MO) with refeeding every 48 to 72 hours.Transformation of immortalized Epstein-Barr virus cell lines The Epstein-Barr virus (EBV)-transformed B-cell lines were prepared and cultured by standard methods.27Induction of apoptosis Fas-mediated apoptosis was induced and assayed in peripheral blood T cells, EBV cell lines, or cell suspensions made from patient tissue with 0.75 µg CH11 or 0.1 µg/mL APO-1, both anti-Fas monoclonal antibodies (MoAbs; Kamiya Biomedical, Thousand Oaks, CA), or as described previously.10,11,23Statistical methods For the analysis of TCR / DNTC results, median values for
the percentage of total T-cell number were compared by the Wilcoxon 2-sample test. The same method was applied to cell death induced by
anti-Fas MoAb in both T and B cells. All statistical tests were 2-tailed.
For estimation of the risk of developing lymphoma, patient years were calculated using the age at the most recent evaluation or when lymphoma was diagnosed. The Poisson distribution was used to determine the probabilities of observing 5 or more non-Hodgkin or Hodgkin lymphoma cases, given the expected numbers (9.4 and 2.6 cases/100 000, respectively) reported in the SEER Cancer Statistics Review for U.S. men and women aged less than 65 years.28 With a median age of 27.8 years (range 1-86 years) and only 5 study individuals with Fas mutations over age 65, the SEER data for the population under age 65 years most closely described the distribution of ages in this study. The 95% confidence interval for the observed to expected ratio was determined, as described.29
Case histories of lymphoma patients In NIH family 3 with a Fas alteration (915A C; T225P; Figure 1)
subject 3-II-3 had anemia, cervical adenopathy, and a
palpable spleen at age 4 years and underwent 2 nondiagnostic lymph node biopsies before a third at age 25 suggested Hodgkin disease.
Chemotherapy and radiation therapy were instituted for stage IIIA
disease; however, he died of extensive disease. The pathologic
specimens were reviewed (by E.S.J.) and reclassified as
histiocyte-rich, T-cell-rich large B-cell lymphoma that was negative
for EBV by in situ hybridization (Figure
2A).30,31 The lymphoma cells were CD20+ but negative for CD30 and CD15 in a background
of T cells and histiocytes.
This individual's brother, subject 3-II-1, had documented cervical and axillary lymphadenopathy by age 3 years. Six biopsies revealed reactive hyperplasia before age 15, when he developed Coombs-positive hemolytic anemia, hepatosplenomegaly, and thrombocytopenia. Splenectomy was performed at age 18. At age 25, further biopsy showed lymphoma (Figure 2B-D), confirmed as an EBV-negative nodular lymphocyte-predominant Hodgkin disease on review. He received combination chemotherapy for stage IIIA disease; however, he relapsed in 1986 and again in 1992. On re-evaluation in 1995, he was free of tumor and asymptomatic, although diffuse peripheral lymphadenopathy persisted. Study of NIH family 26 with a heterozygous Fas alteration (973A Studies of NIH family 30 with a Fas alteration (1074delT; T227fs [frame-shift]; Figure 1) identified female subject 30-II-7 with anemia, adenopathy, and splenomegaly at age 5 weeks, splenectomy and lymph node biopsy at age 7, followed by autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura (ITP). At age 17, a new abdominal mass represented EBV-negative Burkitt lymphoma (Figure 2E,F). She was treated with cyclophosphamide, vincristine, and prednisone. At age 31, she remains free of lymphoma. NIH patient 45-III-2 is a 12-year-old boy who presented with adenopathy, splenomegaly, anemia, and ITP at ages 5 and 7, which led to splenectomy and lymph node biopsy that showed changes typical of ALPS (Table 1).32 At age 10, his Fas mutation (779def11; K181fs [frameshift]; Figure 1) was found. At 11, he lost weight and experienced marked enlargement of lymph nodes in the neck and chest; a biopsy demonstrated Hodgkin disease, EBV-positive, mixed cellularity subtype. He is currently completing multidrug chemotherapy. NIH subject 55-II-1 is a 19-year-old man (Table 1). He
presented with splenomegaly at age 2, underwent splenectomy at age 4, and experienced chronic adenopathy and multiple episodes of thrombocytopenia treated with glucocorticosteroids or intravenous immunoglobulin. A lymph node biopsy at age 4 was nondiagnostic, but 3 biopsies for enlarging axillary, submandibular, and inguinal nodes at
age 17 demonstrated a nonclassifiable B-cell lymphoma with atypical
follicular proliferation and chromosomal rearrangements (Figure 2G-J).
The axillary lymph node was effaced by an atypical follicular
proliferation. The neoplastic cells in it were positive for CD20, CD19,
CD79a, and Bcl-6 but negative for CD10 and bcl-2, suggestive of a
follicle center origin (Bcl-6+) but unusual for follicular
lymphoma (Bcl-2 In New York family 9 with Fas mutations (1003C In New York family P10 with a Fas mutation (IVS7(+2)T6A; P201fs; Figure 1), subject P10-I-1 is a 38-year-old woman with Hodgkin disease, nodular sclerosis type, stage IA, at age 5, treated successfully with local irradiation. Three years later, she developed abdominal and inguinal adenopathy and splenomegaly. Repeat biopsies and splenectomy showed only reactive changes compatible with ALPS,32 but no lymphoma. ITP developed at age 17. An EBV-positive T-cell lymphoma (G3-III-4) in German family
3 with a Fas mutation (1009A No lymphomas were uncovered in the remaining 31 study families. The specific mutations associated with ALPS in all 39 families are shown in Figure 1. Flow cytometry Flow cytometry was performed on peripheral blood lymphocytes from 57 members of the 8 families with lymphomas. Of 36 members with Fas mutations tested, 31 possessed elevated ( 1%) TCR / DNTCs
(median of 4.0%; range 0.5%-75%). All 21 healthy relatives tested
without mutations had significantly lower (< 1%) DNTC percentages (P < .001).
Induction of Fas-mediated apoptosis Fifty-four members of the lymphoma kindreds underwent apoptosis tests. Lymphocytes from 36 individuals with Fas mutations showed depressed lymphocyte apoptosis (median cell loss 5%; range 0%-32%), whereas for 18 subjects lacking Fas mutations, the median percentile of T cells undergoing apoptosis was 44% (range 14%-70%; P < .001). Fas-mediated killing of EBV-transformed B cells was studied in 11 subjects from NIH family 3. In the 4 individuals with mutations, 11% to 25% of B cells died, whereas 33% to 59% of B cells died from 7 relatives with normal Fas alleles (P = .006). Thus, Fas defects result in impaired apoptosis of both B cells and T cells, as noted previously.11Fas-mediated killing and genetics in tumor cells In vitro studies showed that defective apoptosis is a feature of both nonmalignant and lymphomatous cells from ALPS lymph node tissues and that the heterozygous mutation transmitted in the germline is sufficient for the development of lymphoma. Cells from a lymphomatous node of patient 55-II-1 and from a typical nonlymphomatous node from an ALPS patient32 were tested and compared with Jurkat T-cell lymphoma and KK124B Burkitt lymphoma (a gift of Dr Kishor Bhatia) cell lines as well as activated fresh normal human tonsillar lymphocytes. The cells were treated with MoAbs that trigger Fas-mediated cell death or with staurosporine, which kills cells via Fas-independent mitochondrial pathways. Using flow cytometry, it was possible to distinguish the lymphomatous cells from patient 55-II-1 as being relatively large B cells, consistent with their immunohistologic appearance (Figure 2G-I). High percentages of tonsillar lymphocytes, Jurkat cells, and KK124B cells were killed by both apoptosis inducers (Figure 3). Resting lymph node (RLN) cells from ALPS patient 17-II-1 were relatively refractory to Fas-mediated death but sensitive to staurosporine, as expected.19 Both the malignant and nonmalignant lymph node B cells from patient 55-II-1 were refractory to Fas killing but sensitive to staurosporine. Thus, malignant transformation did not introduce or mitigate the inherited apoptotic defect.
Finally, complementary DNAs (cDNAs) prepared from malignant
CD19+ B cells sorted from a node from this patient and
nonmalignant cells of a lymph node from patient 31-III-1
were sequenced. Multiple cDNA clones prepared from proband 55 retained
the 942C Risk of lymphoma development The ratio of observed cases of non-Hodgkin lymphoma (5 cases/3774 patient years, not counting the second lymphoma in subject G3-II-8) among the 130 individuals with mutations to the expected rate among the general population less than 65 years of age (9.4 cases/100 000 patient years)28 was 14 (95% confidence interval [CI] 5- to 33-fold), a significant increase (P < .001). The ratio of observed to expected cases of Hodgkin lymphoma among the general population (5 cases/3774 patient years versus 2.6/100 000 patient years)28 was 51 (95% CI 17- to 119-fold; P < .001).
We examined the possibility that germline Fas mutations and the concomitant defect in lymphocyte apoptosis are hereditary predisposing factors to lymphoma. One hundred thirty members of 39 kindreds that possess inherited Fas mutations were studied; lymphomas cosegregated with Fas mutations in 10 individuals in 8 of the families. These 8 families included 75 members of whom 43, including all 10 individuals with lymphoma, exhibited some or all of the manifestations of ALPS, such as lymphoproliferation, especially of DNTCs, and autoimmunity. The risk of Hodgkin and non-Hodgkin lymphoma in individuals with inherited Fas mutations in our study is 51 and 14 times greater than expected, respectively. We found that both the nonmalignant and malignant lymphocytes from the lymphoma subjects exhibited defective Fas-mediated killing, but they did not have a general apoptosis defect, because the cells responded normally to other apoptosis inducers (Figure 3). A significant feature of lymphoma in ALPS is its diversity.1 The 5 cases of Hodgkin disease were of various types including nodular sclerosing, nodular-lymphocyte predominant, and mixed cellularity. The others represented several histologic types of lymphoma, including a T-cell type, a histiocyte-rich T-cell-rich large B-cell type, a follicular B-cell type, a marginal zone B-cell type, and 2 cases of Burkitt lymphoma. The preponderance of B-cell malignancies is notable given the fact that apoptosis in both T and B cells is abnormal in ALPS and that the major nonmalignant cell types that expand in ALPS are DNTCs, which are believed to be mature T cells that have lost expression of their CD4 and CD8 coreceptors.8,11,19 Therefore, Fas defects do not appear to shift the distribution between T and B lymphoid malignancies. Given that our study group is still small, we cautiously infer that Fas apoptosis deficiency affects a general protective mechanism against B-cell malignancy rather than one that controls a particular B-cell subtype. Such a conclusion would be consistent with evidence that Fas governs the fate of developing B cells in the bone marrow as well as mature B cells in the peripheral immune organs.39 The involvement of Fas mutations in lymphoma is distinct from other apoptosis defects that have been postulated to play a role in lymphoma. Previously, genetic alterations in Bcl-2-related molecules were associated with lymphoid malignancy40-42; however, Bcl-2 protects against an apoptosis pathway emanating from the mitochondrion that was not defective in the lymphoma sample from patient 55 (Figure 3).19 By contrast, Fas is a cell surface receptor that promotes apoptosis in response to a specific inducer, Fas ligand, to govern lymphocyte homeostasis during immune responses.19 The lymphomas we observed are all associated with alterations in the intracytoplasmic region of the Fas receptor, termed the "death domain." Individuals with mutations that affect the death domain have the greatest defect in Fas-mediated apoptosis and the greatest genetic penetrance and severity of clinical symptoms.43,44 Therefore, the propensity to develop B lymphomas relates to the severity of apoptosis defect engendered by specific lesions in the Fas gene, implying that the specific apoptotic function of Fas is of primary importance in protecting against lymphoma. Our findings are in accord with prior data associating defects in Fas function with lymphoid malignancy. Several studies revealed underexpression of Fas in lymphoma45-50 and multiple myeloma,51-54 and somatic chromosomal abnormalities in non-Hodgkin lymphoma in the region of chromosome 10 encoding Fas.55-61 Moreover, somatic Fas mutations have been reported in multiple myeloma, adult T-cell leukemia, childhood T-lineage acute lymphoblastic leukemia,35-37 and in 9 of 150 non-Hodgkin lymphomas.38 Among these 9 cases, 3 were heterozygous and involved the Fas death domain, including 1 with the identical mutation seen in our patient 26-II-4. Three others involved mutations outside the death domain in one allele but deletion of the second Fas allele.38 We demonstrated heterozygosity of the Fas mutation in tumor cells from one of our cases (55-II-1); however, the cumulative evidence indicating that the mutations in all of our patients are dominant-negative implies that all tumors that arose in them involved heterozygous Fas mutations. In our cases, the average age of ALPS onset was 5 years, whereas the average age of lymphoma diagnosis was 28. The cases where somatic alterations in Fas were described in lymphomas more typically arose later in life.35-38 The lag between the manifestations of ALPS and lymphoma could represent time for other genetic or environmental lymphomagenic factors to operate on the substrate of defective apoptosis. This conclusion is supported by studies of mice defective in Fas apoptosis that show lymphoid malignancies arising in conjunction with expression of the L-myc oncogene or as a consequence of aging.7,62-65 The mechanism by which Fas defects in ALPS predispose to lymphomas might involve several components. The most obvious possibility is that a general expansion of the lymphoid pool provides a larger target cell population for other transforming events. This does not seem to fully explain our observations, because the greatest expansions are in T cells, yet we observe B-cell malignancies. Nonetheless, the absolute increases in B cells, which are stimulated by the expanded T helper 1 cells, and marked elevations in IL-10 in ALPS could be important for the increased lymphoma incidence.66 Other, more specific mechanisms could also participate. Defects in the cytolytic pathway for killing virally infected cells mediated by Fas could allow EBV or other oncogenic viruses to persist. A similar apoptotic clearance mechanism may operate on transformed B cells. Because Fas ligand is expressed by T cells and not B cells, T cells could eliminate Fas-sensitive malignant cells. The study of lymphoma in ALPS provides a genetic model of germline Fas deficiency that will allow further examination of these issues.
Drs Howard Britton and Thomas S. DeNapoli informed us of the recent development of Hodgkin disease, mixed cellularity type, in subject 26-IV-5, a 6-year-old boy previously described with ALPS since age 1 (reference 15).
We thank Drs John Bohnsack, Howard Britton, Sandra Buys, Brian Corden, Anthony Infante, Donald Mahoney, Annelise Sitarz, and David Virshup for referring patients for study; the participating families themselves for their cooperation; Ms Jean Whitehouse, Ms Romy Lehmann, and Ms Margaret R. Brown for flow cytometry analysis of peripheral blood; Lindsay A. Middleton, for ascertainment of family data; Dr Maryalice Stetler-Stevenson for flow cytometry analysis of lymph nodes; Drs Lixin Zheng, Gretchen Gibney, Michelle Johnson, and Richard Siegel for assistance with apoptosis assays; Drs Mark Raffeld and Lynn Sorbara for molecular studies; Drs Diane Arthur and Linda Cooley for cytogenetic studies; Dr Douglas Kingma for EBV in situ hybridizations; Uri Lopatin for additional statistical help; Drs Margaret Tucker and Joachim Roesler for helpful discussions; Dr G. Koehler for reviewing selected histologic sections; Drs Louis Staudt and Ian Magrath for critical reviews of the manuscript; and Ms Brenda Rae Marshall for editorial assistance.
Submitted February 11, 2000; accepted March 2, 2001.
The contribution of K.B.E. to this work was supported, in part, by grants from the National Institutes of Health (AR4548I), and the fellowship of C.B. was supported by the Cure for Lymphoma Foundation. A.M.J.P. was supported by the Deutsche Forschungsgememeinschaft (DFG 609/1-1). J.W. was supported by an Arthritis Foundation fellowship.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Stephen E. Straus, LCI, NIAID, 31 Center Dr, Rm 5B-37, National Institutes of Health, Bethesda, MD 20892; e-mail: sstraus{at}nih.gov.
1.
Kramer MH, Hermans J, Wijburg E, et al.
Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
Blood.
1998;92:3152-3162 2. Ong ST, leBeau MM. Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma. Semin Oncol. 1998;25:447-460[Medline] [Order article via Infotrieve].
3.
Aguilera NS, Bijwaard KE, Duncan B, et al.
Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas.
Am J Pathol.
1998;153:1969-1976 4. Ohshima A, Miura I, Hashimoto K, et al. Rearrangements of the BCL6 gene and chromosome aberrations affecting 3q27 in 54 patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1997;27:329-334[Medline] [Order article via Infotrieve].
5.
Korsmeyer SJ.
Bcl-2 initiates a new category of oncogenes: regulators of cell death.
Blood.
1992;80:879-886
6.
Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S.
BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma.
Blood.
1997;90:1168-1174 7. Sneller MC, Straus SE, Jaffe ES, et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest. 1992;90:334-341. 8. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935-946[CrossRef][Medline] [Order article via Infotrieve].
9.
Rieux-Laucat F, LeDeist F, Hivroz C, et al.
Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.
Science.
1995;268:1347-1349
10.
Drappa J, Vaishnaw AK, Sullivan KE, Chu J-L, Elkon KB.
Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.
N Engl J Med.
1996;335:1643-1649
11.
Sneller MC, Wang J, Dale JK, et al.
Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Blood.
1997;89:1341-1348
12.
Bettinardi A, Brugnoni D, Quiròs-Roldan E, et al.
Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis.
Blood.
1997;89:902-909 13. Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr. 1967;70:891-899[CrossRef][Medline] [Order article via Infotrieve]. 14. LeDeist F, Emile J-F, Rieux-Laucat F, et al. Clinical, immunological and pathological consequences of fas-deficient conditions. Lancet. 1996;348:719-723[CrossRef][Medline] [Order article via Infotrieve]. 15. Infante AJ, Britton HA, deNapoli T, et al. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome (ALPS) due to a Fas mutation that impairs lymphocyte apoptosis. J Pediatr. 1998;133:629-633[CrossRef][Medline] [Order article via Infotrieve]. 16. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest. 1996;98:1107-1113[Medline] [Order article via Infotrieve]. 17. Wang J, Zheng L, Lobito A, et al. Inherited human caspase-10 mutations underly defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome, type II. Cell. 1999;98:47-58[CrossRef][Medline] [Order article via Infotrieve].
18.
Dianzani U, Bragardo M, diFranco D, et al.
Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/ lymphoproliferation.
Blood.
1997;89:2871-2879
19.
Lenardo M, Chan KM, Hornung F, et al.
Mature T lymphocyte apoptosis 20. Ju ST, Panka DJ, Cui H, et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995;373:444-448[CrossRef][Medline] [Order article via Infotrieve]. 21. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;377:348-351[CrossRef][Medline] [Order article via Infotrieve]. 22. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kD TNF receptor signals cell death. Cell. 1993;74:845-853[CrossRef][Medline] [Order article via Infotrieve]. 23. Peters AMJ, Kohfink B, Martin H, et al. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. Exp Hematol. 1999;27:868-874[CrossRef][Medline] [Order article via Infotrieve]. 24. Jaffe ES, Raffeld M. Lymphocyte markers in solid tissue. In: Rose NR,deMacario EC,Fahey JL,Friendman H,Penn GM, eds. Manual of Clinical Laboratory Immunology 4th ed. Washington, DC: American Society for Microbiology; 1992:288-297.
25.
Quintanilla-Martinez L, Thieblemont C, Fend F, et al.
Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor.
Am J Pathol.
1998;153:175-182 26. Vaishnaw AK, Orlinick JR, Chu J-L, Krammer PH, Chao MV, Elkon KB. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest. 1999;103:355-363[Medline] [Order article via Infotrieve]. 27. Tosato G. Generation of Epstein-Barr virus immortalized B-cell lines. In: Coligan JE,Kruisbeek AM,Margulies DH,Shevach EM,Strober W, eds. Current Protocols in Immunology. New York, NY: John Wiley & Sons; 1995:7.22.1. 28. Ries LAG,Kosary CL,Hankey BF,Miller BA, eds. SEER Cancer Statistics Review, 1973-1995. Bethesda, MD: National Cancer Institute; 1998. 29. Lilienfeld DE, Stolley PD. Foundations of Epidemiology 3rd ed. New York, NY: Oxford University Press; 1994:302-303. 30. Chittal SM, Brousset P, Voigt J-J, Delsol G. Large B-cell lymphoma rich in T cells and simulating Hodgkin disease. Histopathology. 1991;19:211-220[Medline] [Order article via Infotrieve]. 31. Delabie J, Vandenberghe E, Kennes C, et al. Histiocyte-rich B-cell lymphoma: a distinct clinicopathologic entity possibly related to lymphocyte-predominant Hodgkin disease, paragranuloma subtype. Am J Surg Pathol. 1992;16:37-48[Medline] [Order article via Infotrieve].
32.
Lim MS, Straus SE, Dale JK, et al.
Pathological findings in human autoimmune lymphoproliferative syndrome.
Am J Pathol.
1998;153:1541-1550 33. Flenghi L, Ye BH, Fizzotti M, et al. A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells. Am J Pathol. 1996;147:405-411[Abstract]. 34. Elenitoba-Johnson KS, Kumar S, Lim MS, Kingma DW, Raffeld M, Jaffe ES. Marginal zone B-cell lymphoma with monocytoid B-cell lymphocytes in pediatric patients without immunodeficiency: a report of two cases. Am J Clin Pathol. 1997;107:92-98[Medline] [Order article via Infotrieve].
35.
Landowski TH, Qu N, Buyaksal I, Painter JS, Dalton WS.
Mutations in the Fas antigen in patients with multiple myeloma.
Blood.
1997;90:4266-4270
36.
Tamiya S, Etoh K, Suzushima H, Takatsuki K, Matsuoka M.
Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells.
Blood.
1998;91:3935-3942
37.
Beltinger C, Kurz E, Böhler T, Schrappe M, Ludwig W-D, Debatin K-M.
CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia.
Blood.
1998;91:3943-3951
38.
Grønbæk K, Straten P, Ralfkiaer E, et al.
Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity.
Blood.
1998;92:3018-3024 39. Goodnow CC, Cyster JG, Hartley SB, et al. Self-tolerance checkpoints in B lymphocyte development. Adv Immunol. 1995;59:279-368[Medline] [Order article via Infotrieve]. 40. Lauritzen AF, Moller PH, Nedergaard T, Guldberg P, Hou-Jensen K, Ralfkiaer E. Apoptosis-related genes and proteins in Hodgkin's disease. APMIS. 1999;107:636-644[Medline] [Order article via Infotrieve]. 41. Harada N, Hata H, Yoshida M, et al. Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia. 1998;12:1817-1820[CrossRef][Medline] [Order article via Infotrieve]. 42. Xerri L, Hassoun J, Devilard E, Birnbaum D, Birg F. BCL-X and the apoptotic machinery of lymphoma cells. Leuk Lymphoma. 1998;28:451-458[Medline] [Order article via Infotrieve]. 43. Martin DA, Zheng L, Siegel RM, et al. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome (ALPS), type I. Proc Natl Acad Sci U S A. 1999;96:5442-5447. 44. Jackson CE, Fischer RE, Hsu AP, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Human Genet. 1999;64:1002-1014. 45. Aftabuddin M, Yamadori I, Yoshino T, Kondo E, Akagi T. Correlation between the number of apoptotic cells and expression of the apoptosis-related antigens Fas, Le(y) and bcl-2 protein in non-Hodgkin lymphomas. Pathol Int. 1995;45:422-429[Medline] [Order article via Infotrieve].
46.
Gruss HJ, Dower SK.
Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas.
Blood.
1995;85:3378-3404 47. Kondo E, Yoshino T, Yamadori I, et al. Expression of Bcl-2 protein and Fas antigen in non-Hodgkin lymphomas. Am J Pathol. 1994;145:330-337[Abstract].
48.
Moller P, Henne C, Leithauser F, et al.
Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD43) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas.
Blood.
1993;81:2067-2075 49. Nguyen PL, Harris NL, Ritz J, Robertson MJ. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol. 1996;148:847-853[Abstract].
50.
Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Bensa JC.
Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis.
Blood.
1998;91:2875-2885
51.
Hata H, Matsuzaki H, Takeya M, et al.
Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders.
Blood.
1995;86:1939-1945
52.
Massaia M, Borrione P, Attisano C, et al.
Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients.
Blood.
1995;85:3679-3687
53.
Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T.
Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis.
Blood.
1995;85:757-764
54.
Westendorf JJ, Lammert JM, Jelinek DF.
Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines.
Blood.
1995;85:3566-3576 55. Manolov G, Manolova Y. Marker band in one chromosome 14 from Burkitt's lymphomas. Nature. 1972;237:33-34[CrossRef][Medline] [Order article via Infotrieve]. 56. Juneja S, Lukeis R, Tan L, et al. Cytogenetic analysis of 147 cases of non-Hodgkin lymphoma: non-random chromosomal abnormalities and histological correlations. Br J Haematol. 1990;76:231-237[Medline] [Order article via Infotrieve].
57.
Offit K, Wong G, Filippa DA, Tao Y, Chaganti RS.
Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin lymphoma: clinical correlations.
Blood.
1991;77:1508-1515 58. Offit K, Jhanwar SC, Ladanyi M, Filippa DA, Chaganti RS. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer. 1991;3:189-201[Medline] [Order article via Infotrieve]. 59. Speaks SL, Sanger WG, Masih AS, Harrington DS, Hess M, Armitage JO. Recurrent abnormalities of chromosome bands 10q23-25 in non-Hodgkin lymphoma. Genes Chromosomes Cancer. 1992;5:239-243[Medline] [Order article via Infotrieve]. 60. Lichter P, Walczak H, Weitz S, Behrmann I, Krammer PH. The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19. Genomics. 1992;14:179-180[CrossRef][Medline] [Order article via Infotrieve]. 61. Xerri L, Carbuccia N, Parc P, Birg F. Search for rearrangements and/or allelic loss of the fas/APO-1 gene in 101 human lymphomas. Am J Clin Pathol. 1995;104:424-430[Medline] [Order article via Infotrieve]. 62. Zornig M, Grzeschiczek A, Kowalski MB, Hartmann KY, Moroy T. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene. 1995;10:2397-2401[Medline] [Order article via Infotrieve]. 63. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol. 1991;9:243-269[CrossRef][Medline] [Order article via Infotrieve].
64.
Davidson WF, Giese T, Fredrickson TN.
Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions.
J Exp Med.
1998;187:1825-1838
65.
Peng SL, Robert ME, Hayday AC, Craft J.
A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice.
J Exp Med.
1996;184:1149-1154 66. Fuss IJ, Strober W, Dale JK, et al. Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity. J Immunol. 1997;158:1912-1918[Abstract]. 67. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature. 1996;384:638-641[CrossRef][Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. E. Guicciardi and G. J. Gores Life and death by death receptors FASEB J, June 1, 2009; 23(6): 1625 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Gayed, S Bernatsky, R Ramsey-Goldman, A. Clarke, and C Gordon Lupus and cancer Lupus, May 1, 2009; 18(6): 479 - 485. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Engedal, P. Auberger, and H. K. Blomhoff Retinoic acid regulates Fas-induced apoptosis in Jurkat T cells: reversal of mitogen-mediated repression of Fas DISC assembly J. Leukoc. Biol., March 1, 2009; 85(3): 469 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Stagni, M. G. di Bari, S. Cursi, I. Condo, M. T. Cencioni, R. Testi, Y. Lerenthal, E. Cundari, and D. Barila ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells Blood, January 15, 2008; 111(2): 829 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Xie, R. Patel, T. Wu, J. Zhu, T. Henry, M. Bhaskarabhatla, R. Samudrala, K. Tus, Y. Gong, H. Zhou, et al. PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr Int. Immunol., April 1, 2007; 19(4): 509 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Beneteau, S. Daburon, J.-F. Moreau, J.-L. Taupin, and P. Legembre Dominant-Negative Fas Mutation Is Reversed by Down-expression of c-FLIP Cancer Res., January 1, 2007; 67(1): 108 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Steinhoff, C Assaf, I Anagnostopoulos, C C Geilen, H Stein, and M Hummel Three coexisting lymphomas in one patient: genetically related or only a coincidence? J. Clin. Pathol., December 1, 2006; 59(12): 1312 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Clementi, A. Chiocchetti, G. Cappellano, E. Cerutti, M. Ferretti, E. Orilieri, I. Dianzani, M. Ferrarini, M. Bregni, C. Danesino, et al. Variations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective Fas function Blood, November 1, 2006; 108(9): 3079 - 3084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Del-Rey, J. Ruiz-Contreras, A. Bosque, S. Calleja, J. Gomez-Rial, E. Roldan, P. Morales, A. Serrano, A. Anel, E. Paz-Artal, et al. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome Blood, August 15, 2006; 108(4): 1306 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takahashi, F. Feuerhake, J. L. Kutok, S. Monti, P. Dal Cin, D. Neuberg, J. C. Aster, and M. A. Shipp FAS Death Domain Deletions and Cellular FADD-like Interleukin 1{beta} Converting Enzyme Inhibitory Protein (Long) Overexpression: Alternative Mechanisms for Deregulating the Extrinsic Apoptotic Pathway in Diffuse Large B-Cell Lymphoma Subtypes. Clin. Cancer Res., June 1, 2006; 12(11): 3265 - 3271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Castellano, B. Vire, M. Pion, V. Quivy, D. Olive, I. Hirsch, C. Van Lint, and Y. Collette Active Transcription of the Human FASL/CD95L/TNFSF6 Promoter Region in T Lymphocytes Involves Chromatin Remodeling: ROLE OF DNA METHYLATION AND PROTEIN ACETYLATION SUGGEST DISTINCT MECHANISMS OF TRANSCRIPTIONAL REPRESSION J. Biol. Chem., May 26, 2006; 281(21): 14719 - 14728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Le Clorennec, I. Youlyouz-Marfak, E. Adriaenssens, J. Coll, G. W. Bornkamm, and J. Feuillard EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-{kappa}B, STAT1, and p53 Blood, March 1, 2006; 107(5): 2070 - 2078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Re, R. Kuppers, and V. Diehl Molecular Pathogenesis of Hodgkin's Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6379 - 6386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Roesler, J.-M. Izquierdo, M. Ryser, A. Rosen-Wolff, M. Gahr, J. Valcarcel, M. J. Lenardo, and L. Zheng Haploinsufficiency, rather than the effect of an excessive production of soluble CD95 (CD95{Delta}TM), is the basis for ALPS Ia in a family with duplicated 3' splice site AG in CD95 intron 5 on one allele Blood, September 1, 2005; 106(5): 1652 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Abramson and M. A. Shipp Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach Blood, August 15, 2005; 106(4): 1164 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Q. Zhang, C. Okumura, T. McCarty, M. S. Shin, P. Mukhopadhyay, M. Hori, T. A. Torrey, Z. Naghashfar, J. X. Zhou, C. H. Lee, et al. Evidence for Selective Transformation of Autoreactive Immature Plasma Cells in Mice Deficient in Fasl J. Exp. Med., December 6, 2004; 200(11): 1467 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Puck and S. E. Straus Somatic Mutations -- Not Just for Cancer Anymore N. Engl. J. Med., September 30, 2004; 351(14): 1388 - 1390. [Full Text] [PDF]
|
|
|
|
|
|
R. Clementi, L. Dagna, U. Dianzani, L. Dupre, I. Dianzani, M. Ponzoni, A. Cometa, A. Chiocchetti, M. G. Sabbadini, C. Rugarli, et al. Inherited Perforin and Fas Mutations in a Patient with Autoimmune Lymphoproliferative Syndrome and Lymphoma N. Engl. J. Med., September 30, 2004; 351(14): 1419 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Jaffe Common Threads of Mucosa-Associated Lymphoid Tissue Lymphoma Pathogenesis: From Infection to Translocation J Natl Cancer Inst, April 21, 2004; 96(8): 571 - 573. [Full Text] [PDF]
|
|
|
|
|
|
S. Mathas, A. Lietz, I. Anagnostopoulos, F. Hummel, B. Wiesner, M. Janz, F. Jundt, B. Hirsch, K. Johrens-Leder, H.-P. Vornlocher, et al. c-FLIP Mediates Resistance of Hodgkin/Reed-Sternberg Cells to Death Receptor-induced Apoptosis J. Exp. Med., April 19, 2004; 199(8): 1041 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Hsiao, K.-W. Liao, S.-W. Hung, and R.-M. Chu Tumor-Infiltrating Lymphocyte Secretion of IL-6 Antagonizes Tumor-Derived TGF-{beta}1 and Restores the Lymphokine-Activated Killing Activity J. Immunol., February 1, 2004; 172(3): 1508 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Greil, G. Anether, K. Johrer, and I. Tinhofer Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools J. Leukoc. Biol., September 1, 2003; 74(3): 311 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sanchez-Beato, A. Sanchez-Aguilera, and M. A. Piris Cell cycle deregulation in B-cell lymphomas Blood, February 15, 2003; 101(4): 1220 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Maggio, A. van den Berg, D. de Jong, A. Diepstra, and S. Poppema Low Frequency of FAS Mutations in Reed-Sternberg Cells of Hodgkin's Lymphoma Am. J. Pathol., January 1, 2003; 162(1): 29 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-o. Lee, J. M. Herndon, R. Barreiro, T. S. Griffith, and T. A. Ferguson TRAIL: A Mechanism of Tumor Surveillance in an Immune Privileged Site J. Immunol., November 1, 2002; 169(9): 4739 - 4744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. L. Chiu, E. Ivakine, S. Mortin-Toth, and J. S. Danska Susceptibility to Lymphoid Neoplasia in Immunodeficient Strains of Nonobese Diabetic Mice Cancer Res., October 15, 2002; 62(20): 5828 - 5834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Khouri, B. Tuan, K. Grant, J. J.H. Bleesing, T. A. Fleisher, L. J. McCarthy, W. Dzik, D. B. Cines, and V. S. Blanchette Immune Thrombocytopenic Purpura N. Engl. J. Med., August 8, 2002; 347(6): 449 - 450. [Full Text] [PDF]
|
|
|
|
|
|
X. Shi, C. Xie, D. Kreska, J. A. Richardson, and C. Mohan Genetic Dissection of SLE: SLE1 and FAS Impact Alternate Pathways Leading to Lymphoproliferative Autoimmunity J. Exp. Med., August 5, 2002; 196(3): 281 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takayama, T. Takakuwa, Y. Tsujimoto, Y. Tani, N. Nonomura, A. Okuyama, S. Nagata, and K. Aozasa Frequent Fas Gene Mutations in Testicular Germ Cell Tumors Am. J. Pathol., August 1, 2002; 161(2): 635 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Morse III, M. R. Anver, T. N. Fredrickson, D. C. Haines, A. W. Harris, N. L. Harris, E. S. Jaffe, S. C. Kogan, I. C. M. MacLennan, P. K. Pattengale, et al. Bethesda proposals for classification of lymphoid neoplasms in mice Blood, June 17, 2002; 100(1): 246 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Igney and P. H. Krammer Immune escape of tumors: apoptosis resistance and tumor counterattack J. Leukoc. Biol., June 1, 2002; 71(6): 907 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Arkwright, M. Abinun, and A. J. Cant Autoimmunity in human primary immunodeficiency diseases Blood, April 15, 2002; 99(8): 2694 - 2702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Himmel, F. Bi, H. Shen, N. A. Jenkins, N. G. Copeland, Y. Zheng, and D. A. Largaespada Activation of Clg, a Novel Dbl Family Guanine Nucleotide Exchange Factor Gene, by Proviral Insertion at Evi24, a Common Integration Site in B Cell and Myeloid Leukemias J. Biol. Chem., April 12, 2002; 277(16): 13463 - 13472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kim, K. A. Whartenby, R. W. Georgantas III, J. Wingard, and C. I. Civin Human CD34+ Hematopoietic Stem/Progenitor Cells Express High Levels of FLIP and Are Resistant to Fas-Mediated Apoptosis Stem Cells, March 1, 2002; 20(2): 174 - 182. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
CD8
genes were examined by polymerase chain reaction (PCR) and showed no clonal bands.
light chain expression was detected by flow cytometry.
Two of the node biopsies showed identical clonal cytogenetic
abnormalities with unbalanced translocations involving multiple
chromosomes. His peripheral blood showed a heterozygous Fas mutation
(942C
immune regulation in a dynamic and unpredictable antigenic environment.
Annu Rev Immunol.
1999;17:221-253